Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Six-week, six-shot regimen fights hayfever for more than one season

12.03.2003


Johns Hopkins researchers last year reported that an experimental treatment for severe ragweed allergy consisting of just six shots in six weeks dramatically reduced allergic symptoms such as runny nose, nasal congestion and sneezing, and nearly eliminated the need for relief medications like antihistamines and decongestants. Now, follow-up of patients who continued in the study for a second year, shows that the initial six-injection course of this treatment appears to be effective – and safe – for more than one allergy season.



"We are particularly pleased that this brief, six-week, six-injection regimen can have lasting positive effects for more than one season of ragweed exposure," said Peter Creticos, M.D., associate professor of medicine at Johns Hopkins and principal investigator of the study. "These studies represent a major advance in the development of new treatments for allergic disease, especially when compared with conventional allergy treatments, which can take years to be effective," he added.

The new treatment is an allergy vaccine created by attaching immune-system-boosting molecules, or oligonucleotides, to Amb 1 a, the major ragweed protein responsible for allergic reactions.


Creticos will present the new findings of the Johns Hopkins study on March 11 at a special symposium on "Allergy Therapeutics" at the 60th annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI).

The observer-blinded, placebo-controlled Phase II study evaluated adult volunteers who had a history of fall seasonal hayfever and had skin test reactions to ragweed pollen. Using a vaccine developed by scientists at University of California, San Diego, and produced by Dynavax Technologies Corporation of Berkeley, Calif., Johns Hopkins investigators gave patients the new treatment before the 2001 ragweed season. These patients were followed for their clinical improvement throughout the 2001 and 2002 ragweed seasons – without additional injections of the vaccine.

The follow-up phase of the study showed that patients given the vaccine had improved hayfever symptoms, quality of life measurements, and less need for relief medications during the second ragweed season and these changes were similar to those observed during the initial ragweed season.

Other investigators in the study are Joseph Eiden, David Broide, Susan Balcer-Whaley, John Schroeder, Arouna Khattignavong, Huamin Li, Philip Norman and Robert Hamilton.

This research was performed as part of the Immune Tolerance Network, with support from the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Juvenile Diabetes Research Foundation.


Dr. Creticos is a paid consultant to Dynavax Technologies. Another member of the JHU Division of Clinical Immunology is a paid consultant to and owns equity in the company

Trent Stockton | EurekAlert!
Further information:
http://www.hopkinsmedicine.org/
http://www.hopkinsmedicine.org/press/2002/MARCH/020302.htm
http://www.hopkins-allergy.org/

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Underwater acoustic localization of marine mammals and vehicles

23.11.2017 | Information Technology

Enhancing the quantum sensing capabilities of diamond

23.11.2017 | Physics and Astronomy

Meadows beat out shrubs when it comes to storing carbon

23.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>